INCY vs OCUL · P/E 14, rev $5.14B vs rev $24.3M
Incyte Corporation (INCY) versus Ocular Therapeutix Inc (OCUL) — a side-by-side from cached financials, not a winner call.
Incyte Corporation (INCY) is a biotechnology company listed on US.
Ocular Therapeutix Inc (OCUL) is a biotechnology company listed on US.
Latest reported INCY revenue for 2025-12-31 was $5.14B. Net income was $1.29B. Revenue was up 21.2% from 2024-12-31 to 2025-12-31. INCY currently screens at market cap $20.45B and trailing P/E 14.5.
Latest reported OCUL revenue for 2026-06-30 was $24.3M. Net income was -$167.4M. OCUL currently screens at market cap $1.76B.
INCY currently screens at market cap $20.45B and trailing P/E 14.5. OCUL currently screens at market cap $1.76B.
Not investment advice. Open the INCY and OCUL stock pages for the full models.
Not investment advice.